en Gastroenterology Gastroenterology Original Research Original Research <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><span style="font-style:italic"><b><span style="font-size:9.0pt"><span style="font-style:normal">Background: </span></span></b><span style="font-size:9.0pt">Helicobacter pylori</span><span style="font-size:9.0pt"><span style="font-style:normal"> infection is a prevalent global health issue, especially in developing countries. Due to increasing antibiotic resistance, sequential therapy regimens have been proposed as alternatives to standard treatment. This study aimed to evaluate the efficacy and safety of a 1-week sequential regimen containing furazolidone and metronidazole compared to the standard triple therapy for </span></span><span style="font-size:9.0pt">H. pylori</span><span style="font-size:9.0pt"><span style="font-style:normal"> eradication.</span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><span style="font-style:italic"><b><span style="font-size:9.0pt"><span style="font-style:normal">&nbsp;&nbsp; Methods: </span></span></b><span style="font-size:9.0pt"><span style="font-style:normal">In this randomized, parallel-group clinical trial, 110 patients with confirmed </span></span><span style="font-size:9.0pt">H. pylori</span><span style="font-size:9.0pt"><span style="font-style:normal"> infection were randomly assigned to either the intervention group (sequential therapy) or the control group (standard regimen). The primary outcome was </span></span><span style="font-size:9.0pt">H. pylori</span><span style="font-size:9.0pt"><span style="font-style:normal"> eradication assessed by stool antigen test 4 weeks after treatment. Secondary outcomes included adverse effects. Data were analyzed using chi-square and other appropriate statistical tests.</span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><span style="font-style:italic"><b><span style="font-size:9.0pt"><span style="font-style:normal">&nbsp;&nbsp; Results: </span></span></b><span style="font-size:9.0pt"><span style="font-style:normal">The eradication rate was significantly higher in the intervention group than in the control group (76.4% vs. 56.4%, &chi;&sup2; = 4.928, </span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal"> = 0.043). Adverse events were less frequent in the intervention group, including nausea (16.4% vs. 23.6%, </span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal"> = 0.03), altered taste (10.9% vs. 18.2%, </span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal"> = 0.002), loss of appetite (7.3% vs. 14.5%, </span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal"> = 0.006), and dizziness (5.5% vs. 0%, </span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal"> = 0.048).</span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><span style="font-style:italic"><b><span style="font-size:9.0pt"><span style="font-style:normal">&nbsp;&nbsp; Conclusion: </span></span></b><span style="font-size:9.0pt"><span style="font-style:normal">The 1-week sequential regimen demonstrated significantly higher eradication rates and better tolerability compared to the standard triple therapy. This approach may offer a more effective and safer option for treating </span></span><span style="font-size:9.0pt">H. pylori</span><span style="font-size:9.0pt"><span style="font-style:normal"> infection.</span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><span style="font-style:italic"><b><span style="font-size:9.0pt"><span style="font-style:normal"></span></span></b></span></span></span></span></span></span><br> &nbsp; Helicobacter Pylori, Furazolidone, Proton Pump Inhibitor (PPI), Metronidazole, Antibiotics 1148 1153 http://mjiri.iums.ac.ir/browse.php?a_code=A-10-4532-2&slc_lang=en&sid=1 Mohammad Taher Tahermohammad38@gmail.com 200319475328460094257 200319475328460094257 No Faculty of Nursing and Midwifery, Saveh University of Medical Sciences, Saveh, Iran Mahdieh Esfandiari Mahdiehesfandiary@yahoo.com 200319475328460094258 0009-0005-7789-1598 No Department of Internal Medicine, Arak University of Medical Sciences, Arak, Iran Hamid Abredari hamid_abredari@yahoo.com 200319475328460094259 200319475328460094259 No Faculty of Nursing and Midwifery, Saveh University of Medical Sciences, Saveh, Iran Kouros Aghazade Sarhangipour kouros_aghazade_s@yahoo.com 200319475328460094260 200319475328460094260 No Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran Leila Taheri taheri.leila@ymail.com 200319475328460094261 200319475328460094261 No Faculty of Nursing and Midwifery, Qom University of Medical Sciences, Qom, Iran Leila Ghanbari-Afra ghanbari.afra91@yahoo.com 200319475328460094262 200319475328460094262 No Faculty of Nursing and Midwifery, Qom University of Medical Sciences, Qom, Iran Mohammad Reza Rouhani mohamadreza.rohani@yahoo.com 200319475328460094263 200319475328460094263 Yes Department of Internal Medicine, Saveh University of Medical Sciences, Saveh, Iran